Search Results - "Mclornan, Donal P."

Applying Synthetic Lethality for the Selective Targeting of Cancer by McLornan, Donal P, List, Alan, Mufti, Ghulam J

“…Synthetic lethality refers to the requirement that two defects be present for cell death to occur. When an agent damages DNA, its effects on the cell can be…”
Get full text

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress? by Mahdi, Dina, Spiers, Jessica, Rampotas, Alexandros, Polverelli, Nicola, McLornan, Donal P

“…Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many…”
Get full text

Bone marrow niche dysregulation in myeloproliferative neoplasms by Curto-Garcia, Natalia, Harrison, Claire, McLornan, Donal P

“…The bone marrow niche is a complex and dynamic structure composed of a multitude of cell types which functionally create an interactive network facilitating…”
Get full text

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 by McLornan, Donal P, Yakoub-Agha, Ibrahim, Robin, Marie, Chalandon, Yves, Harrison, Claire N, Kroger, Nicolaus

“…Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to…”
Get full text

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey by Passweg, Jakob R., Baldomero, Helen, Ciceri, Fabio, Corbacioglu, Selim, de la Cámara, Rafael, Dolstra, Harry, Glass, Bertram, Greco, Raffaella, McLornan, Donal P., Neven, Bénédicte, de Latour, Régis Peffault, Perić, Zinaida, Ruggeri, Annalisa, Snowden, John A., Sureda, Anna

“…In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 patients received…”
Get full text

Editorial: 50 years of BMT: risk stratification, donor matching and stem cell collection for transplantation by Hamerschlak, Nelson, Gómez-Almaguer, David, McLornan, Donal P

Get full text

‘Fine tuning’ Conditioning Protocols for Myelofibrosis to Reduce Graft Failure: are we making progress? by McLornan, Dr. Donal P.

Get full text

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia by Harrington, Patrick, Dillon, Richard, Radia, Deepti, Rousselot, Philippe, McLornan, Donal P, Ong, Mark, Green, Anna, Verde, Alessandro, Hussain, Farzana, Raj, Kavita, Kordasti, Shahram, Harrison, Claire, De Lavallade, Hugues

“…Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially…”
Get full text

Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms by Herlihy, Naoimh, Harrison, Claire N, McLornan, Donal P

Get full text

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia by Gunawan, Arief S, McLornan, Donal P, Wilkins, Bridget, Waghorn, Katherine, Hoade, Yvette, Cross, Nicholas C P, Harrison, Claire N

Get full text

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry by Hernández‐Boluda, Juan‐Carlos, Pereira, Arturo, Kröger, Nicolaus, Cornelissen, Jan J., Finke, Jürgen, Beelen, Dietrich, Witte, Moniek, Wilson, Keith, Platzbecker, Uwe, Sengeloev, Henrik, Blaise, Didier, Einsele, Hermann, Sockel, Katja, Krüger, William, Lenhoff, Stig, Salaroli, Adriano, Martin, Hans, García‐Gutiérrez, Valentín, Pavone, Vicenzo, Alvarez‐Larrán, Alberto, Raya, José‐María, Zinger, Nienke, Gras, Luuk, Hayden, Patrick, Czerw, Tomasz, P. McLornan, Donal, Yakoub‐Agha, Ibrahim

“…Allogeneic hematopoietic cell transplantation (allo‐HCT) is increasingly used in older myelofibrosis (MF) patients, but its risk/benefit ratio compared to…”
Get full text

Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT by Drozd-Sokolowska, Joanna, Gras, Luuk, Koster, Linda, Martino, Rodrigo, Salas, María Queralt, Salmenniemi, Urpu, Zudaire, Teresa, Yañez, Lucrecia, Bellido, Mar, Collin, Matthew, Kaufmann, Martin, Kozlowski, Piotr, Poiré, Xavier, Ferra, Christelle, Sampol, Antònia, Wilson, Keith M O, Cairoli, Anne, Gedde-Dahl, Tobias, Deconinck, Eric, Mirabile, Milena, Suarez, Felipe, Raj, Kavita, Van Gelder, Michel, Yakoub-Agha, Ibrahim, Tournilhac, Olivier, McLornan, Donal P

Get full text

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012 by McLornan, Donal P., Mead, Adam J., Jackson, Graham, Harrison, Claire N.

“…Summary Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical therapeutic options are currently limited. The role of allogeneic…”
Get full text

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations by Alimam, Samah, McLornan, Donal P, Jiang, Jie, Radia, Deepti, Mufti, Ghulam J, Harrison, Claire N

Get full text

Current and future status of JAK inhibitors by McLornan, Donal P, Pope, Janet E, Gotlib, Jason, Harrison, Claire N

“…An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling in multiple disease…”
Get full text

Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis by Dowse, Robin, Ibrahim, Maria, McLornan, Donal P., Moonim, Mufaddal T., Harrison, Claire N., Radia, Deepti H.

Get full text

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys) by Okikiolu, Jumoke, Woodley, Claire, Cadman-Davies, Llywelyn, O'Sullivan, Jennifer, Radia, Deepti, Garcia, Natalia Curto, Harrington, Patrick, Kordasti, Shahram, Asirvatham, Susan, Sriskandarajah, Priya, Saunders, Jamie, Saha, Chandan, Sanchez, Irene, deLavallade, Hugues, McLornan, Donal P, Harrison, Claire N

“…Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly…”
Get full text

Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT by Gurnari, Carmelo, McLornan, Donal P.

“…VEXAS (acronym for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) is a fascinating new entity encompassing a variety of clinical manifestations,…”
Get full text

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis by Oh, Stephen T., Verstovsek, Srdan, Gupta, Vikas, Platzbecker, Uwe, Devos, Timothy, Kiladjian, Jean‐Jacques, McLornan, Donal P., Perkins, Andrew, Fox, Maria Laura, McMullin, Mary Frances, Mead, Adam J., Egyed, Miklos, Mayer, Jiri, Sacha, Tomasz, Kawashima, Jun, Huang, Mei, Strouse, Bryan, Mesa, Ruben

“…Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association…”
Get full text

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis by McMullin, Mary F. F., Mead, Adam J., Ali, Sahra, Cargo, Catherine, Chen, Frederick, Ewing, Joanne, Garg, Mamta, Godfrey, Anna, Knapper, Steven, McLornan, Donal P., Nangalia, Jyoti, Sekhar, Mallika, Wadelin, Frances, Harrison, Claire N.

Get full text